Akèy › Kansè nan tete › Alabama
Etid klinik pou Kansè nan tete nan Alabama
29 etid pou Kansè nan tete ap chèche patisipan nan sit nan Alabama.
Vil nan Alabama
Tèks ofisyèl etid la (Anglè)
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
- Central Alabama Research, Birmingham
Ap rekriteFaz 3
Laj 18 a 100 · Tout sèks · Mizajou Oct 2, 2026 · NCT05827081A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- UAB O'Neal Comprehensive Cancer Center - The Kirklin Clinic of UAB Hospital, Birmingham
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT06760819A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
- Alabama Oncology, Birmingham
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT06369285PRE-ISPY Phase I/II Oncology Platform Program
- The University of Alabama at Birmingham O'Neal Comprehensive Cancer Center, Birmingham
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT05868226Phase II Single Arm Trial of Low Dose Capecitabine in Patients With Advanced Breast Cancer
- University of Alabama at Birmingham, Birmingham
Ap rekriteFaz 2
Laj 60 ak plis · Fanm · Mizajou Sep 30, 2026 · NCT06105684A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
- Southern Cancer Center (SCC) ( Site 8000), Daphne
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT07060807An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors
- University of Alabama At Birmingham Hospital, Birmingham
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT07222267A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
- Research Site, Daphne
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06103864Improved Successful Retrieval Rate of HydroMARK Plus Breast Biopsy Site Marker in Comparison to HydroMARK as Well as Improved Surgeon Satisfaction
- The Kirklin Clinic, Birmingham
Ap rekrite
Laj 18 a 90 · Fanm · Mizajou Sep 25, 2026 · NCT06294574A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
- University of Alabama at Birmingham, Birmingham
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 23, 2026 · NCT06618287A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
- University of Alabama at Birmingham, Birmingham
Ap rekriteFaz 2
Laj 18 ak plis · Fanm · Mizajou Sep 22, 2026 · NCT07287098Women Informed to Screen Depending on Measures of Risk (Wisdom Study)
- University of Alabama at Birmingham, Birmingham
Ap rekriteVolontè an sante akeyi
Laj 30 a 74 · Fanm · Mizajou Sep 21, 2026 · NCT02620852A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
- Southern Cancer Center, PC, Daphne
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 15, 2026 · NCT06492616Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
- University of Alabama Birmingham, Birmingham
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 10, 2026 · NCT06293898Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies
- Birmingham Hematology Associates, Birmingham
Ap rekriteEtid obsèvasyon
Laj 18 a 99 · Tout sèks · Mizajou Sep 3, 2026 · NCT07211178TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd
- University of Alabama, Birmingham
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Aug 26, 2026 · NCT06533826Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
- Southern Cancer Center, Mobile
Ap rekriteFaz 3
Laj 18 a 100 · Tout sèks · Mizajou Aug 6, 2026 · NCT05232916Comparison of Breast Cancer Screening With CESM to DBT in Women With Dense Breasts
- University of Alabama, Birmingham, Birmingham
Ap rekriteVolontè an sante akeyi
Laj 45 a 74 · Fanm · Mizajou Jul 31, 2026 · NCT05625659Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
- Uni of Alabama at Birmingham, Birmingham
Ap rekriteFaz 1
Laj 18 a 100 · Tout sèks · Mizajou Jul 29, 2026 · NCT06562192Promoting Resilience in Women With Breast Cancer (PRISM -MBC)
- The University of Alabama, Birmingham
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou May 15, 2026 · NCT06855654I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
- University of Alabama at Birmingham, Birmingham
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou May 6, 2026 · NCT01042379Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
- University of Alabama at Birmingham, Birmingham
- University of South Alabama, Mobile
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Apr 30, 2026 · NCT05297734De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
- University of South Alabama Mitchell Cancer Institute, Mobile
Ap rekriteFaz 3
Laj 50 a 70 · Tout sèks · Mizajou Apr 23, 2026 · NCT04852887A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer
- University of Alabama at Birmingham, Birmingham
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Feb 25, 2026 · NCT06099769Positron Emission Tomography (PET) Imaging With Zirconium-89 (89Zr)-Trastuzumab for Prediction of HER2 Targeted Therapy Effectiveness
- The Kirklin Clinic, Birmingham
Ap rekriteFaz 1 bonè
Laj 18 ak plis · Fanm · Mizajou Jan 26, 2026 · NCT03321045Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort
- University of Alabama Birmingham, Birmingham
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jan 20, 2026 · NCT05693766Time-Restricted Eating and Cancer: Clinical Outcomes, Mechanisms, and Moderators
- The University of Alabama at Birmingham, Birmingham
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Dec 16, 2025 · NCT04722341RAD 1802: Pilot Trial of Five Fraction Stereotactic Body Radiotherapy for Early Stage Breast Cancer Patients Eligible for Post-Operative Accelerated Partial Breast Irradiation (APBI)
- University of Alabama at Birmingham (UAB) Hazelrig-Salter Radiation Oncology Center (HSROC), Birmingham
Ap rekrite
Laj 18 a 99 · Tout sèks · Mizajou Oct 31, 2025 · NCT03643861SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Birmingham
- Massive Bio SYNERGY-AI site, Mobile
Ap rekriteEtid obsèvasyon
Tout laj · Tout sèks · Mizajou Oct 28, 2025 · NCT03452774Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.